Categories Earnings, Health Care

Agilent Technologies (NYSE: A): Q4 2019 Earnings Snapshot

— Agilent Technologies (NYSE: A) reported its fourth-quarter 2019 adjusted earnings of $0.89 per share versus $0.85 per share expected.

— Revenue grew by 6% to $1.37 billion versus $1.33 billion expected.

Agilent Technologies Q4 2019 Earnings Snapshot

— Life Sciences and Applied Markets Group sales rose 4% on continued strength in Environmental & Forensics markets.

— Agilent CrossLab Group grew by 8% on broad growth across major markets and regions, while Diagnostics and Genomics Group saw 5% growth aided by Pathology and Companion Dx and ongoing demand in Pharma for oligo-manufacturing.

— Looking ahead into the first quarter of 2020, the company expects revenue in the range of $1.34-1.355 billion and adjusted earnings of $0.80-0.81 per share. Analysts expect EPS of $0.84 on revenue of $1.38 billion.

— For the full year 2020, the company predicts revenue in the range of $5.50-5.55 billion and adjusted earnings of $3.38-3.43 per share. The consensus estimates EPS of $3.44 on revenue of $5.55 billion.

We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

Abbott Laboratories (ABT) Q2 2025 sales and earnings beat estimates

Abbott Laboratories (NYSE: ABT) on Thursday announced financial results for the second quarter of fiscal 2025, reporting an increase in sales and adjusted profit. The results also exceeded Wall Street's

US Bancorp (USB) Earnings: 2Q25 Key Numbers

US Bancorp (NYSE: USB) reported its second quarter 2025 earnings results today. Total net revenue increased 2% year-over-year to $7 billion. Net income applicable to US Bancorp common shareholders rose

Key highlights from GE Aerospace’s (GE) Q2 2025 earnings results

GE Aerospace (NYSE: GE) reported its second quarter 2025 earnings results today. Total revenue increased 21% year-over-year to $11 billion. Adjusted revenue grew 23% to $10.1 billion. Net income attributable to

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top